optinose
FDA accepts sNDA for Optinose’s XHANCE
May 5, 2023Medical Communications Ear Nose & throat, FDA, Nasal Spray, optinose, sNDA
Optinose has announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
